Snapshot

The Emergency Use Authorization pathway has been developed by the of Sierra Leone.

This pathway can be used where COVID-19 vaccines and therapeutics: new chemical entity; generics; biologicals; medical devices; blood products; post approval changes (variations).

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

When relevant, the agency relies on prior decisions from WHO

Target time assessment is .